Pharmacogenetic analysis of INT 0144 trial: association of polymorphisms with survival and toxicity in rectal cancer patients treated with 5-FU and radiation

Purpose: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate...

Full description

Saved in:
Bibliographic Details
Main Authors: Bohanes, Pierre (Author) , Ulrich, Cornelia (Author)
Format: Article (Journal)
Language:English
Published: 14 January 2015
In: Clinical cancer research
Year: 2015, Volume: 21, Issue: 7, Pages: 1583-1590
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-14-0857
Online Access:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1158/1078-0432.CCR-14-0857
Verlag, kostenfrei, Volltext: http://clincancerres.aacrjournals.org/content/21/7/1583
Get full text
Author Notes:Pierre Bohanes, Cathryn J. Rankin, Charles D. Blanke, Thomas Winder, Cornelia M. Ulrich, Stephen R. Smalley, Tyvin A. Rich, James A. Martensen, Al B. Benson, Robert J. Mayer, Christine M. Cripps, Kathleen Danenberg, Karen W. Makar, Wu Zhang, Jacqueline K. Benedetti, and Heinz-Josef Lenz

MARC

LEADER 00000caa a2200000 c 4500
001 1561168750
003 DE-627
005 20230428162119.0
007 cr uuu---uuuuu
008 170725s2015 xx |||||o 00| ||eng c
024 7 |a 10.1158/1078-0432.CCR-14-0857  |2 doi 
035 |a (DE-627)1561168750 
035 |a (DE-576)491168756 
035 |a (DE-599)BSZ491168756 
035 |a (OCoLC)1340977601 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Bohanes, Pierre  |e VerfasserIn  |0 (DE-588)1137223790  |0 (DE-627)894210483  |0 (DE-576)491168608  |4 aut 
245 1 0 |a Pharmacogenetic analysis of INT 0144 trial  |b association of polymorphisms with survival and toxicity in rectal cancer patients treated with 5-FU and radiation  |c Pierre Bohanes, Cathryn J. Rankin, Charles D. Blanke, Thomas Winder, Cornelia M. Ulrich, Stephen R. Smalley, Tyvin A. Rich, James A. Martensen, Al B. Benson, Robert J. Mayer, Christine M. Cripps, Kathleen Danenberg, Karen W. Makar, Wu Zhang, Jacqueline K. Benedetti, and Heinz-Josef Lenz 
264 1 |c 14 January 2015 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 25.07.2017 
520 |a Purpose: We tested whether 18 polymorphisms in 16 genes (GSTP1, COX2, IL10, EGFR, EGF, FGFR4, CCDN1, VEGFR2, VEGF, CXCR2, IL8, MMP3, ICAM1, ERCC1, RAD51, and XRCC3) would predict disease-free survival (DFS), overall survival (OS), and toxicity in the INT0144 trial, which was designed to investigate different postoperative regimens of 5-fluorouracil (5-FU)-based chemoradiation (CRT) in locally advanced rectal cancers: Arm 1 consisted of bolus 5-FU followed by 5-FU protracted venous infusion (PVI) with radiotherapy; arm 2 was induction and concomitant PVI 5-FU with radiotherapy and arm 3 was induction and concomitant bolus 5-FU with radiotherapy. Experimental Design: DNA from 746 stage II/III rectal patients enrolled in the Southwest Oncology Group (SWOG) S9304 phase III trial was analyzed. Genomic DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) tumor tissue. The polymorphisms were analyzed using direct DNA-sequencing or polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Results: GSTP1-Ile105Val (rs1695) was significantly associated with DFS and OS and its effect did not vary by treatment arm. The five-year DFS and OS were 53% and 58%, respectively, for G/G, 66% and 72% for G/A, and 57% and 66% for A/A patients. In arm 2, IL8-251A/A genotype (rs4073) was associated with a lower risk of toxicities (P = 0.04). The VEGFR2 H472Q Q/Q genotype (rs1870377) was associated with a higher risk of grade 3-5 proximal upper gastrointestinal tract (PUGIT) mucositis (P = 0.04) in arm 2. However, in arm 1, this genotype was associated with a lower risk of PUGIT mucositis (P = 0.004). Conclusion: rs1695 may be prognostic in patients with rectal cancer treated with adjuvant CRT. rs4073 and rs1870377 may exhibit different associations with toxicity, according to the 5-FU schedule. Clin Cancer Res; 21(7); 1583-90. ©2015 AACR. 
700 1 |a Ulrich, Cornelia  |d 1967-  |e VerfasserIn  |0 (DE-588)1045797030  |0 (DE-627)775130133  |0 (DE-576)399253289  |4 aut 
773 0 8 |i Enthalten in  |t Clinical cancer research  |d Philadelphia, Pa. [u.a.] : AACR, 1995  |g 21(2015), 7, Seite 1583-1590  |h Online-Ressource  |w (DE-627)325489971  |w (DE-600)2036787-9  |w (DE-576)094502234  |x 1557-3265  |7 nnas  |a Pharmacogenetic analysis of INT 0144 trial association of polymorphisms with survival and toxicity in rectal cancer patients treated with 5-FU and radiation 
773 1 8 |g volume:21  |g year:2015  |g number:7  |g pages:1583-1590  |g extent:8  |a Pharmacogenetic analysis of INT 0144 trial association of polymorphisms with survival and toxicity in rectal cancer patients treated with 5-FU and radiation 
856 4 0 |u http://dx.doi.org/10.1158/1078-0432.CCR-14-0857  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u http://clincancerres.aacrjournals.org/content/21/7/1583  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20170725 
993 |a Article 
994 |a 2015 
998 |g 1045797030  |a Ulrich, Cornelia  |m 1045797030:Ulrich, Cornelia  |d 50000  |e 50000PU1045797030  |k 0/50000/  |p 5 
999 |a KXP-PPN1561168750  |e 2975103891 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Pierre Bohanes, Cathryn J. Rankin, Charles D. Blanke, Thomas Winder, Cornelia M. Ulrich, Stephen R. Smalley, Tyvin A. Rich, James A. Martensen, Al B. Benson, Robert J. Mayer, Christine M. Cripps, Kathleen Danenberg, Karen W. Makar, Wu Zhang, Jacqueline K. Benedetti, and Heinz-Josef Lenz"]},"person":[{"family":"Bohanes","role":"aut","roleDisplay":"VerfasserIn","display":"Bohanes, Pierre","given":"Pierre"},{"role":"aut","roleDisplay":"VerfasserIn","family":"Ulrich","display":"Ulrich, Cornelia","given":"Cornelia"}],"title":[{"title_sort":"Pharmacogenetic analysis of INT 0144 trial","subtitle":"association of polymorphisms with survival and toxicity in rectal cancer patients treated with 5-FU and radiation","title":"Pharmacogenetic analysis of INT 0144 trial"}],"id":{"doi":["10.1158/1078-0432.CCR-14-0857"],"eki":["1561168750"]},"recId":"1561168750","physDesc":[{"extent":"8 S."}],"language":["eng"],"relHost":[{"id":{"issn":["1557-3265"],"eki":["325489971"],"zdb":["2036787-9"]},"physDesc":[{"extent":"Online-Ressource"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.1995 -"],"corporate":[{"display":"American Association for Cancer Research","role":"isb","roleDisplay":"Herausgebendes Organ"}],"disp":"Pharmacogenetic analysis of INT 0144 trial association of polymorphisms with survival and toxicity in rectal cancer patients treated with 5-FU and radiationClinical cancer research","recId":"325489971","language":["eng"],"note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"],"part":{"issue":"7","volume":"21","pages":"1583-1590","extent":"8","text":"21(2015), 7, Seite 1583-1590","year":"2015"},"origin":[{"publisherPlace":"Philadelphia, Pa. [u.a.]","dateIssuedKey":"1995","dateIssuedDisp":"1995-","publisher":"AACR"}],"name":{"displayForm":["American Association for Cancer Research"]},"title":[{"title_sort":"Clinical cancer research","title":"Clinical cancer research"}]}],"note":["Gesehen am 25.07.2017"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"14 January 2015"}]} 
SRT |a BOHANESPIEPHARMACOGE1420